Citigroup; JPMorgan; Morgan Stanley; Qatalyst Partners; Skye Gould/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
While M&A had a down year during the pandemic, bankers still orchestrated a number of megadeals.
Insider partnered with the financial-data platform MergerLinks to identify 2020 s top 20 bankers.
The ranking is based lead investment bankers who arranged the largest M&A deals in North America.
For Wall Street s rainmakers, the start of 2020 was a nightmare.
Mergers and acquisitions temporarily went over a cliff in the springtime as the world was met with a series of lockdowns and strict restrictions to confront the spread of the coronavirus. In the dealmaking drought in the first half of the year, global volumes collapsed to $1.2 trillion, a 41% decline from 2019, with megadeals taking the brunt of it, falling 69%, according to data from Ref
Market players such as
Sanofi, Rigel Pharmaceuticals, Kissei Pharmaceutical, Sobi, Shionogi & Co., Ltd., Amgen, Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta, Takeda, Argenx, GC Pharma, Omeros Corporation, Biotest, Millennium Pharmaceuticals, Cellphire, Momenta Pharmaceuticals, ILTOO Pharma, Genosco, and several others are involved in developing Thrombocytopenia therapies.
Thrombocytopenia market might experience significant growth due to the expected launch of upcoming therapies such as
Rozanolixizumab (UCB7665); Rilzabrutinib (PRN-1008); BAX930; Efgartigimod (ARGX-113); Cablivi (caplacizumab); Tavalisse/Tavlesse (Fostamatinib); Doptelet (Avatrombopag); Nplate (Romiplostim); and Mulpleta (lusutrombopag), and others.
For additional information on Market Impact by Therapies, visit:
Thrombocytopenia is a condition in which the blood has a lower than a normal number of platelets. The condition can be inherited or acquired. Thrombocytopenia causes, somet
Pemphigus Market Top Scenario, SWOT Analysis, Business Overview, Forecast 2023 sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Sanofi gains access to antibody tech with Kymab acquisition
French pharma will receive global rights to phase 2a monoclonal antibody
Sanofi has made a $1.45bn play for Cambridge, UK-based Kymab, extending its reach into immunotherapy and immunology.
As part of the acquisition, Sanofi will have full global rights to Kymab’s monoclonal antibody (mAb) KY1005 – an asset with a novel mechanism of action that has the potential to treat a range of immune-mediated disorders and inflammatory diseases.
The mAb recently met both primary endpoints in a phase 2a study in moderate-to-severe atopic dermatitis patients whose disease is inadequately controlled by topical corticosteroids.